UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000036384
Receipt No. R000041433
Scientific Title A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function
Date of disclosure of the study information 2020/10/20
Last modified on 2022/10/04 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function
Acronym A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function
Scientific Title A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function
Scientific Title:Acronym A clinical study to evaluate the effects of fish oil containing DHA on the preservation of renal function
Region
Japan

Condition
Condition Healthy volunteers
Classification by specialty
Not applicable Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate the effects of fish oil containing DHA on the preservation of renal function
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Changes of markers of renal function (eGFR, creatinine)
Key secondary outcomes Changes of markers of renal function (creatinine clearance), Changes of markers relating to renal impairment (urinary L-FABP, albumin/creatinine, NAG, KIM-1, angiotensinogen), Changes of blood pressure, glucose metabolic markers (HbA1c, blood glucose), lipid markers (LDL-C, TG, HDL-C), body weight and other clinical test values

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Intake of capsules (fish oil containing DHA) for 24 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
45 years-old <=
Age-upper limit
74 years-old >=
Gender Male
Key inclusion criteria 1) Males between the ages of 45 and 74 years old
2) Subjects whose results at the screening examination fall into either of the following
・ Systolic blood pressure >= 130 mmHg or diastolic blood pressure >= 85 mmHg
・ Fasting blood glucose >= 110 mg/dL
・ Spot urine albumin/creatinine >= 10 mg/g・Cr
Key exclusion criteria 1) Subjects who take medicines having the effect on the present study (diuretics, antihypertensive agents, SGLT2 inhibitors, warfarin, uricosuric agents, etc.)
2) Subjects who take foods for specified health uses, foods with function claims labeled or supplements (reducing triglycerides, blood pressure, blood glucose and having the effects on dysuria) which can affect the data in a main study
3) Subjects with dysuria who cannot collect their urine
4) Subjects receiving a medical history of serious liver disorder, renal disorder or heart diseases
5) Subjects receiving a medical treatment or having a medical history of hepatitis
6) Subjects who have terrible anemia
7) Subjects who have addiction to alcohol
8) Subjects who need assistance by others and who cannot walk independently
9) Subjects who are bleeding (hemophilia, capillary vulnerability, digestive tract ulcer, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage, etc.)
10) Subjects who have the possibility of developing allergic symptoms by the test food
11) Subjects having a medical history of hypersensitivity to the test food
12) Subjects currently participating in other clinical trials or planning to participate in other clinical trials during the examination period
13) Subjects who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study
14) Subjects deemed unsuitable by the investigator
Target sample size 35

Research contact person
Name of lead principal investigator
1st name Shinya
Middle name
Last name Ashida
Organization Maruha Nichiro Corporation
Division name Central Research Institute
Zip code 300-4295
Address 16-2, Wadai, Tsukuba, Ibaraki
TEL 029-864-6708
Email s-ashida@maruha-nichiro.co.jp

Public contact
Name of contact person
1st name Tomohiro
Middle name
Last name Sugino
Organization Soiken Inc.
Division name R&D Division
Zip code 560-0082
Address Senri Life Science Center 13F,1-4-2, Shinsenre-higashimachi, Toyonaka, Osaka
TEL 06-6871-8888
Homepage URL
Email sugino@soiken.com

Sponsor
Institute Soiken Inc.
Institute
Department

Funding Source
Organization Maruha Nichiro Corporation
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization IRB of Fukuda Clinic
Address Shin-Osaka Brick Building 2F, 1-6-1, Miyahara, Yodogawa-ku, Osaka, Osaka
Tel 06-6398-0203
Email fukudaclinicIRB@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 10 Month 20 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2018 Year 10 Month 20 Day
Date of IRB
2018 Year 10 Month 20 Day
Anticipated trial start date
2019 Year 04 Month 06 Day
Last follow-up date
2019 Year 10 Month 20 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 04 Month 02 Day
Last modified on
2022 Year 10 Month 04 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000041433